Gian Luca Forni

List of Publications by Year
in descending order

141 papers	5,352 citations	109321 35 h-index	88630 70 g-index
141 all docs	141 docs citations	141 times ranked	4936 citing authors

#	Article	IF	Citations
1	Risk factors for endocrine complications in transfusion-dependent thalassemia patients on chelation therapy with deferasirox: a risk assessment study from a multi-center nation-wide cohort. Haematologica, 2022, 107, 467-477.	3.5	11
2	Italian patients with hemoglobinopathies exhibit a 5â€fold increase in ageâ€standardized lethality due to SARSâ€CoVâ€2 infection. American Journal of Hematology, 2022, 97, .	4.1	7
3	Mortality in Î²-thalassemia patients with confirmed pulmonary arterial hypertension on right heart catheterization. Blood, 2022, 139, 2080-2083.	1.4	10
4	Transfusional Approach in Multi-Ethnic Sickle Cell Patients: Real-World Practice Data From a Multicenter Survey in Italy. Frontiers in Medicine, 2022, 9, 832154.	2.6	2
5	Good Clinical Practice of the Italian Society of Thalassemia and Haemoglobinopathies (SITE) for the Management of Endocrine Complications in Patients with Haemoglobinopathies. Journal of Clinical Medicine, 2022, 11, 1826.	2.4	2
6	Tricuspid-valve regurgitant jet velocity as a risk factor for death in Î²-Thalassemia. Haematologica, 2022, , .	3.5	0
7	Thalassaemia is paradoxically associated with a reduced risk of inâ€hospital complications and mortality in COVIDâ€19: Data from an international registry. Journal of Cellular and Molecular Medicine, 2022, 26, 2520-2528.	3.6	6
8	Quality of Life and Burden of Disease in Italian Patients with Transfusion-Dependent Beta-Thalassemia. Journal of Clinical Medicine, 2022, 11, 15.	2.4	12
9	Selecting Î²-thalassemia Patients for Gene Therapy: A Decision-making Algorithm. HemaSphere, 2021, 5, e555.	2.7	4
10	Complex Modes of Inheritance in Hereditary Red Blood Cell Disorders: A Case Series Study of 155 Patients. Genes, 2021, 12, 958.	2.4	22
11	Recommendations for diagnosis and treatment of methemoglobinemia. American Journal of Hematology, 2021, 96, 1666-1678.	4.1	56
12	Changing patterns of thalassaemia in Italy: a WebThal perspective. Blood Transfusion, 2021, 19, 261-268.	0.4	2
13	The Increased Burden of Sickle Cell Disease in Italy: Findings from the Greatalys (Generating Real) Tj ETQq1 1 0.784314 rgBT /Overloc	1.4	1
14	Hemoglobinopathies and Cancer: Preliminary Results of an Italian Multicenter Experience. Blood, 2021, 138, 946-946.	1.4	0
15	Summary of Joint European Hematology Association (EHA) and EuroBloodNet Recommendations on Diagnosis and Treatment of Methemoglobinemia. HemaSphere, 2021, 5, e660.	2.7	1
16	Luspatercept Improves Quality of Life and Reduces Red Blood Cell Transfusion Burden in Patients with Non-Transfusion-Dependent Î²-Thalassemia in the BEYOND Trial. Blood, 2021, 138, 3081-3081.	1.4	4
17	Fyn specifically Regulates the activity of red cell glucose-6-phosphate-dehydrogenase. Redox Biology, 2020, 36, 101639.	9.0	14
18	Management of Iron Overload in Beta-Thalassemia Patients: Clinical Practice Update Based on Case Series. International Journal of Molecular Sciences, 2020, 21, 8771.	4.1	25

#	Article	IF	Citations
19	A relative ADAMTS13 deficiency supports the presence of a secondary microangiopathy in COVID 19. Thrombosis Research, 2020, 193, 170-172.	1.7	57
20	Manual erythroexchange in sickle cell disease: multicenter validation of a protocol predictive of volume to exchange and hemoglobin values. Annals of Hematology, 2020, 99, 2047-2055.	1.8	3
21	Recommendations for Pregnancy in Rare Inherited Anemias. HemaSphere, 2020, 4, e446.	2.7	8
22	Changing patterns in the epidemiology of Î²â€thalassemia. European Journal of Haematology, 2020, 105, 692-703.	2.2	122
23	Development of Algorithm for Clinical Management of Sickle Cell Bone Disease: Evidence for a Role of Vertebral Fractures in Patient Follow-up. Journal of Clinical Medicine, 2020, 9, 1601.	2.4	12
24	COVID-19 in a Patient with Î²-Thalassemia Major and Severe Pulmonary Arterial Hypertension. Hemoglobin, 2020, 44, 218-220.	0.8	9
25	<scp>SARSâ€CoV</scp>â€2 infection in beta thalassemia: Preliminary data from the Italian experience. American Journal of Hematology, 2020, 95, E198-E199.	4.1	56
26	Risk factors for heart disease in transfusion-dependent thalassemia: serum ferritin revisited. Internal and Emergency Medicine, 2019, 14, 365-370.	2.0	13
27	Management of the aging beta-thalassemia transfusion-dependent population â€“ The Italian experience. Blood Reviews, 2019, 38, 100594.	5.7	32
28	Sickle cell disease: a review for the internist. Internal and Emergency Medicine, 2019, 14, 1051-1064.	2.0	61
29	Stem Cell Modeling of Neuroferritinopathy Reveals Iron as a Determinant of Senescence and Ferroptosis during Neuronal Aging. Stem Cell Reports, 2019, 13, 832-846.	4.8	46
30	Noninvasive liver fibrosis assessment in chronic viral hepatitis C: agreement among 1D transient elastography, 2D shear wave elastography, and magnetic resonance elastography. Abdominal Radiology, 2019, 44, 4011-4021.	2.1	14
31	Current challenges in the management of patients with sickle cell disease â€“ A report of the Italian experience. Orphanet Journal of Rare Diseases, 2019, 14, 120.	2.7	24
32	Efficacy and safety of deferiprone for the treatment of superficial siderosis: results from a long-term observational study. Neurological Sciences, 2019, 40, 1357-1361.	1.9	13
33	Access to emergency departments for acute events and identification of sickle cell disease in refugees. Blood, 2019, 133, 2100-2103.	1.4	24
34	Sotatercept, a novel transforming growth factor Î² ligand trap, improves anemia in Î²-thalassemia: a phase II, open-label, dose-finding study. Haematologica, 2019, 104, 477-484.	3.5	61
35	A Multicenter, Italian Trial of Early Iron Chelation Therapy with Low Dose Deferasirox (ExjadeÂ®) in Patients with Low/Intermediate-1 Risk MDS at the Beginning of Transfusional Story. Blood, 2019, 134, 4256-4256.	1.4	3
36	Selecting ÃŸ-Thalassemia Patients for Gene Therapy: A Decision-Making Algorithm. Blood, 2019, 134, 972-972.	1.4	2

#	Article	IF	Citations
37	Fyn Specifically Regulates the Activity of Red Cell Glucose-6-Phosphate-Dehydrogenase. Blood, 2019, 134, 3527-3527.	1.4	0
38	Red blood cell alloimmunisation in transfusion-dependent thalassaemia: a systematic review. Blood Transfusion, 2019, 17, 4-15.	0.4	28
39	Renal safety under longâ€course deferasirox therapy in iron overloaded transfusionâ€dependent Î²â€thalassemia and other anemias. American Journal of Hematology, 2018, 93, E172-E175.	4.1	11
40	Multiâ€gene panel testing improves diagnosis and management of patients with hereditary anemias. American Journal of Hematology, 2018, 93, 672-682.	4.1	117
41	Lack of correlation between heart, liver and pancreas <scp>MRI</scp>â€<scp>R</scp>2*: Results from longâ€term followâ€up in a cohort of adult Î²â€thalassemia major patients. American Journal of Hematology, 2018, 93, E79-E82.	4.1	14
42	Real-life experience with hydroxyurea in sickle cell disease: A multicenter study in a cohort of patients with heterogeneous descent. Blood Cells, Molecules, and Diseases, 2018, 69, 82-89.	1.4	34
43	Hydroxyurea prescription, availability and use for children with sickle cell disease in Italy: Results of a National Multicenter survey. Pediatric Blood and Cancer, 2018, 65, e26774.	1.5	29
44	Daily alternating deferasirox and deferiprone therapy successfully controls iron accumulation in untreatable transfusionâ€dependent thalassemia patients. American Journal of Hematology, 2018, 93, E338-E340.	4.1	6
45	Hematopoietic Cell Transplantation in Thalassemia and Sickle Cell Disease: Report from the European Society for Blood and Bone Marrow Transplantation Hemoglobinopathy Registry: 2000-2017. Blood, 2018, 132, 168-168.	1.4	9
46	Transfusion Therapy in a Multi-Ethnic Sickle Cell Population Real-World Practice. a Preliminary Data Analysis of Multicentre Survey. Blood, 2018, 132, 2389-2389.	1.4	3
47	GDF15 and Erythroferrone Mark Erythropoietic Response to ACE-011 (Sotatercept) in Thalassemia. Blood, 2018, 132, 3633-3633.	1.4	0
48	Noninvasive monitoring of liver fibrosis in sickle cell disease: Longitudinal observation of a cohort of adult patients. American Journal of Hematology, 2017, 92, E666-E668.	4.1	9
49	Treatment of hepatitis C virus infection with directâ€acting antiviral drugs is safe and effective in patients with hemoglobinopathies. American Journal of Hematology, 2017, 92, 1349-1355.	4.1	42
50	Is there a standard-of-care for transfusion therapy in thalassemia?. Current Opinion in Hematology, 2017, 24, 558-564.	2.5	10
51	Pseudoxanthoma Elasticum-Like in Î²-Thalassemia Major, a matter of Î±-Klotho and Parathyroid Hormone?. Hemoglobin, 2017, 41, 254-259.	0.8	3
52	Patient Affected by Beta-Propeller Protein-Associated Neurodegeneration: A Therapeutic Attempt with Iron Chelation Therapy. Frontiers in Neurology, 2017, 8, 385.	2.4	18
53	Management of betaâ€thalassemiaâ€“associated osteoporosis. Annals of the New York Academy of Sciences, 2016, 1368, 73-81.	3.8	31
54	Comparison between different software programs and post-processing techniques for the MRI quantification of liver iron concentration in thalassemia patients. Radiologia Medica, 2016, 121, 751-762.	7.7	11

#	Article	IF	Citations
55	Dual therapy with peg-interferon and ribavirin in thalassemia major patients with chronic HCV infection: Is there still an indication?. Digestive and Liver Disease, 2016, 48, 650-655.	0.9	11
56	Renal Safety after More Than a Decade of Deferasirox Use in Patients with Transfusional Hemosiderosis. Blood, 2016, 128, 2466-2466.	1.4	2
57	Safety and Efficacy of Direct-Acting Antiviral Drugs in Patients with Haemoglobinophaties and Chronic Hepatitis C Infection. Blood, 2016, 128, 3627-3627.	1.4	0
58	Iron overloadâ€related heart failure in a patient with transfusionâ€dependent myelodysplastic syndrome reversed by intensive combined chelation therapy. Clinical Case Reports (discontinued), 2015, 3, 952-954.	0.5	4
59	A genetic score for the prediction of beta-thalassemia severity. Haematologica, 2015, 100, 452-457.	3.5	45
60	Characterization of ferromagnetic or conductive properties of metallic foreign objects embedded within the human body with magnetic iron detector (MID): Screening patients for MRI. Magnetic Resonance in Medicine, 2015, 73, 2030-2037.	3.0	4
61	Deferasirox effect on renal haemodynamic parameters in patients with transfusionâ€dependent Î² thalassaemia. British Journal of Haematology, 2015, 168, 882-890.	2.5	27
62	Klotho, a new marker for osteoporosis and muscle strength in Î²-thalassemia major. Blood Cells, Molecules, and Diseases, 2015, 55, 396-401.	1.4	24
63	Determination of deferasirox plasma concentrations: do gender, physical and genetic differences affect chelation efficacy?. European Journal of Haematology, 2015, 94, 310-317.	2.2	19
64	SF3B1 Mutation Is an Independent Predictor of Parenchymal Iron Overload in Myelodysplastic Syndromes. Blood, 2015, 126, 1678-1678.	1.4	4
65	Luspatercept (ACE-536) Reduces Disease Burden, Including Anemia, Iron Overload, and Leg Ulcers, in Adults with Beta-Thalassemia: Results from a Phase 2 Study. Blood, 2015, 126, 752-752.	1.4	8
66	Hepatocellular carcinoma in thalassaemia: an update of the Italian Registry. British Journal of Haematology, 2014, 167, 121-126.	2.5	69
67	Development of interactive algorithm for clinical management of acute events related to sickle cell disease in emergency department. Orphanet Journal of Rare Diseases, 2014, 9, 91.	2.7	14
68	Efficacy and safety of sildenafil for the treatment of severe pulmonary hypertension in patients with hemoglobinopathies: results from a long-term follow up. Haematologica, 2014, 99, e17-e18.	3.5	14
69	Prevalence and Risk Factors for Pulmonary Arterial Hypertension in a Large Group of Î²-Thalassemia Patients Using Right Heart Catheterization. Circulation, 2014, 129, 338-345.	1.6	101
70	Efficacy and safety of deferiprone for the treatment of pantothenate kinase-associated neurodegeneration (PKAN) and neurodegeneration with brain iron accumulation (NBIA): Results from a four years follow-up. Parkinsonism and Related Disorders, 2014, 20, 651-654.	2.2	80
71	Deferiprone Versus Deferoxamine in Thalassemia Intermedia: Results from 5-Year Long-Term Italian Multi-Center Randomized Clinical Trial. Blood, 2014, 124, 1354-1354.	1.4	2
72	Antibodies reacting with Simian virus 40 mimotopes in serum samples from patients with thalassaemia major. Blood Transfusion, 2014, 12, 464-70.	0.4	4

#	Article	IF	Citations
73	The Impact of Comorbidities on Clinical Outcome of Patients with Myelodysplastic Syndromes: A Real-Life Survey. Blood, 2014, 124, 4668-4668.	1.4	0
74	The Prognostic Role of Diabetes Mellitus for Cardiac Complications in a Large Cohort of Well Treated Thalassemia Major Patients. Blood, 2014, 124, 4043-4043.	1.4	0
75	Diagnostic value of real-time elastography in the assessment of hepatic fibrosis in patients with liver iron overload. European Journal of Radiology, 2013, 82, e755-e761.	2.6	21
76	Assessment and management of iron overload in Î²â€thalassaemia major patients during the 21st century: a realâ€life experience from the <scp>I</scp>talian <scp>W</scp>ebthal project. British Journal of Haematology, 2013, 161, 872-883.	2.5	31
77	Transferrin-immune complex disease: A potentially overlooked gammopathy mediated by IgM and IgG. American Journal of Hematology, 2013, 88, 1045-1049.	4.1	9
78	Differential effects of the type of iron chelator on the absolute number of hematopoietic peripheral progenitors in patients with Â-thalassemia major. Haematologica, 2013, 98, 555-559.	3.5	12
79	Changes in the quality of life of people with thalassemia major between 2001 and 2009. Patient Preference and Adherence, 2013, 7, 231.	1.8	36
80	A Phase 2a, Open-Label, Dose-Finding Study To Determine The Safety and Tolerability Of Sotatercept (ACE-011) In Adults With Beta (Î²)-Thalassemia: Interim Results. Blood, 2013, 122, 3448-3448.	1.4	14
81	A phase 2 study of the safety, tolerability, and pharmacodynamics of FBS0701, a novel oral iron chelator, in transfusional iron overload. Blood, 2012, 119, 3263-3268.	1.4	48
82	Neridronate improves bone mineral density and reduces back pain in Î²â€thalassaemia patients with osteoporosis: results from a phase 2, randomized, parallelâ€arm, openâ€label study. British Journal of Haematology, 2012, 158, 274-282.	2.5	36
83	Two-Year Renal Hemodynamic Effects of Deferasirox in Patients with Transfusion-Dependent Î²-Thalassemia. Blood, 2012, 120, 3257-3257.	1.4	2
84	CYBRD1 as a modifier gene that modulates iron phenotype in HFE p.C282Y homozygous patients. Haematologica, 2012, 97, 1818-1825.	3.5	34
85	Iron Chelation Therapy and Mobilization of Hematopoietic Peripheral Progenitors in Patients with Î²-Thalassemia Major. Blood, 2012, 120, 5178-5178.	1.4	0
86	Estimation of the Prevalence of Pulmonary Artery Hypertension in a Large Group of Î²-Thalassemia Patients Using Right Heart Catheterization. Blood, 2012, 120, 3262-3262.	1.4	0
87	A pilot trial of deferiprone for neurodegeneration with brain iron accumulation. Haematologica, 2011, 96, 1708-1711.	3.5	122
88	Longâ€term safety and efficacy of deferasirox (Exjade^{Â®}) for up to 5â€ƒyears in transfusional ironâ€overloaded patients with sickle cell disease. British Journal of Haematology, 2011, 154, 387-397.	2.5	67
89	Response of iron overload to deferasirox in rare transfusionâ€dependent anaemias: equivalent effects on serum ferritin and labile plasma iron for haemolytic or production anaemias. European Journal of Haematology, 2011, 87, 338-348.	2.2	28
90	Changing patterns of splenectomy in transfusionâ€dependent thalassemia patients. American Journal of Hematology, 2011, 86, 808-810.	4.1	32

#	Article	IF	Citations
91	Musculoskeletal Manifestations of Chronic Anemias. Seminars in Musculoskeletal Radiology, 2011, 15, 269-280.	0.7	26
92	On T2* Magnetic Resonance and Cardiac Iron. Circulation, 2011, 123, 1519-1528.	1.6	381
93	Clinical management of cardiovascular complications in patients with thalassaemia major: a large observational multicenter study. European Journal of Echocardiography, 2011, 12, 242-246.	2.3	16
94	Safety, Tolerability and Dose Response of FBS0701, a Novel Iron Chelator for Treatment of Transfusional Iron Overload: Results of a 24-Week Multicenter, International Phase 2 Study. Blood, 2011, 118, 690-690.	1.4	0
95	Daily alternating deferasirox and deferiprone therapy for â€œhardâ€toâ€chelateâ€Î²â€thalassemia major patients. American Journal of Hematology, 2010, 85, 460-461.	4.1	38
96	Mutational spectrum in congenital dyserythropoietic anemia type II: Identification of 19 novel variants in SEC23B gene. American Journal of Hematology, 2010, 85, 915-920.	4.1	40
97	Manual erythroexchange for chronic transfusion therapy in patients with sickle cell syndromes unresponsive to hydroxyurea: A longâ€term followâ€up. American Journal of Hematology, 2010, 85, 974-974.	4.1	8
98	Venous-Like Leg Ulcers without Venous Insufficiency in Congenital Anemia: Successful Treatment Using Compression Bandages. Dermatologic Surgery, 2010, 36, 1336-1340.	0.8	6
99	Pregnancy and Â-thalassemia: an Italian multicenter experience. Haematologica, 2010, 95, 376-381.	3.5	103
100	Neridronate (NE) for the Treatment of Osteoporosis In Patients with Î²-Thalassemia: Results from an Italian Multicenter Randomized, Open Label, Phase II Trial. Blood, 2010, 116, 4282-4282.	1.4	2
101	Long-Term Safety and Efficacy of Deferasirox (ExjadeÂ®) In Transfused Patients with Sickle Cell Disease Treated for up to 5 Years. Blood, 2010, 116, 845-845.	1.4	1
102	Cholelithiasis in thalassemia major. European Journal of Haematology, 2009, 82, 22-25.	2.2	29
103	The influence of treatment in specialized centers on survival of patients with thalassemia major. American Journal of Hematology, 2009, 84, 317-318.	4.1	23
104	Relative response of patients with myelodysplastic syndromes and other transfusionâ€dependent anaemias to deferasirox (ICL670): a 1â€yr prospective study. European Journal of Haematology, 2008, 80, 168-176.	2.2	210
105	Regression of symptoms after selective iron chelation therapy in a case of neurodegeneration with brain iron accumulation. Movement Disorders, 2008, 23, 904-907.	3.9	70
106	Acquired iron overload associated with antitransferrin monoclonal immunoglobulin: A case report. American Journal of Hematology, 2008, 83, 932-934.	4.1	6
107	Effect of Food, Type of Food, and Time of Food Intake on Deferasirox Bioavailability: Recommendations for an Optimal Deferasirox Administration Regimen. Journal of Clinical Pharmacology, 2008, 48, 428-435.	2.0	36
108	Standardized T2* Map of a Normal Human Heart to Correct T2* Segmental Artefacts; Myocardial Iron Overload and Fibrosis in Thalassemia IntermediaVersusThalassemia Major Patients and Electrocardiogram Changes in Thalassemia Major Patients. Hemoglobin, 2008, 32, 97-107.	0.8	20

#	Article	IF	Citations
109	Patient-Reported Outcomes of Deferasirox (ExjadeÂ®, ICL670) versus Deferoxamine in Sickle Cell Disease Patients with Transfusional Hemosiderosis. Acta Haematologica, 2008, 119, 133-141.	1.4	56
110	New TFR2 mutations in young Italian patients with hemochromatosis. Haematologica, 2008, 93, 309-310.	3.5	35
111	Deferasirox (ExjadeÂ®) in Pediatric Patients with Î²-Thalassemia: Update of 4.7-Year Efficacy and Safety from Extension Studies. Blood, 2008, 112, 3883-3883.	1.4	5
112	Cumulative Efficacy and Safety of 5-Year Deferasirox (ExjadeÂ®) Treatment in Pediatric Patients with Thalassemia Major: A Phase II Multicenter Prospective Trial. Blood, 2008, 112, 5413-5413.	1.4	6
113	Cardiac and Liver Magnetic Resonance Characterization of Thalassemia Intermedia Patients: A Comparative Multicenter Study Versus Thalassemia Major Patients. Blood, 2008, 112, 5421-5421.	1.4	0
114	Effect of Iron Chelators on Cardiac Iron Assessed by MR T2* in Thalassemia Major. Blood, 2008, 112, 3886-3886.	1.4	0
115	Prevalence, Clinical and Instrumental Correlates of Myocardial Fibrosis and Necrosis by Delayed Contrast Enhancement Cardiovascular Magnetic Resonace in Thalassemia Major Patients. Blood, 2008, 112, 5424-5424.	1.4	0
116	Manual Erythro-Exchange (MEEX) to Prevent Complications of Sickle Cell Disease in Patients Unresponsive to Hydroxyurea: A Long-Term Follow-up. Blood, 2008, 112, 4815-4815.	1.4	0
117	Efficacy and Safety of 1 Yearâ€™s Treatment with Deferasirox (ExjadeÂ®): Assessment of Regularly Transfused Patients with Diamond-Blackfan Anemia Enrolled in the EPIC Study.. Blood, 2008, 112, 1048-1048.	1.4	9
118	A randomised comparison of deferasiroxversusdeferoxamine for the treatment of transfusional iron overload in sickle cell disease. British Journal of Haematology, 2007, 136, 501-508.	2.5	255
119	Long-Term Efficacy and Safety with Deferasirox (ExjadeÂ®, ICL670), a Once-Daily Oral Iron Chelator, in Pediatric Patients.. Blood, 2007, 110, 2774-2774.	1.4	9
120	Cardiovascular Involvement in Thalassemia Major Patients: WEB-THALÂ® Data Analysis (A Web-Based) Tj ETQq0 0 0 rgBT /Overlock 10 T	1.4	0
121	Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. Blood, 2006, 107, 3733-3737.	1.4	338
122	Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica, 2006, 91, 873-80.	3.5	210
123	Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with beta-thalassemia major. Haematologica, 2006, 91, 1343-51.	3.5	109
124	Therapeutic Approaches to Pulmonary Hypertension in Hemoglobinopathies: Efficacy and Safety of Sildenafil in the Treatment of Severe Pulmonary Hypertension in Patients with Hemoglobinopathy. Annals of the New York Academy of Sciences, 2005, 1054, 471-475.	3.8	10
125	Genetic and clinical heterogeneity of ferroportin disease. British Journal of Haematology, 2005, 131, 663-670.	2.5	64
126	Incidence of Pulmonary Hypertension in Haemoglobinopathic Patients without Left Ventricular Disfunction.. Blood, 2005, 106, 2691-2691.	1.4	3

#	Article	IF	Citations
127	Calibration of Myocardial T2* Values in Post-Mortem Hearts.. Blood, 2005, 106, 3837-3837.	1.4	3
128	Preliminary Results of Full Body Iron Overload Measurement by a Magnetic Susceptometer.. Blood, 2005, 106, 3714-3714.	1.4	0
129	Multi-Centre Validation of the Cardiovascular Magnetic Resonance Multi Breath-Hold T2* Technique for Myocardial Iron Quantification in Thalassaemia Major.. Blood, 2005, 106, 3828-3828.	1.4	0
130	Efficacy and safety of sildenafil in the treatment of severe pulmonary hypertension in patients with hemoglobinopathies. Haematologica, 2005, 90, 452-8.	3.5	91
131	Hepatocellular carcinoma in the thalassaemia syndromes. British Journal of Haematology, 2004, 124, 114-117.	2.5	147
132	Clinical and histological characterization of liver disease in patients with transfusion-dependent beta-thalassemia. A multicenter study of 117 cases. Haematologica, 2004, 89, 1179-86.	3.5	49
133	Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica, 2004, 89, 1187-93.	3.5	772
134	Typical manifestation of acute congestive heart failure in patients with Thalassaemia major causing diagnostic delay in the emergency room. European Journal of Heart Failure, 2003, 5, 607-608.	7.1	9
135	Nonrandom Xâ€Chromosome Inactivation in Hemopoietic Cells from Carriers of Dyskeratosis Congenita. American Journal of Human Genetics, 1997, 61, 458-461.	6.2	0
136	Quantitative Texture Analysis in Twoâ€Dimensional Echocardiography. Echocardiography, 1996, 13, 9-20.	0.9	5
137	G6PD deficiency-related chronic hemolysis treated with splenectomy: A case report. American Journal of Hematology, 1994, 47, 146-147.	4.1	2
138	Dyskeratosis Congenita: Unusual Presenting Features Within a Kindred. Pediatric Hematology and Oncology, 1993, 10, 145-149.	0.8	22
139	A new glucose-6-phosphate dehydrogenase variant with congenital nonspherocytic hemolytic anemia (G6PD Genova). Human Genetics, 1990, 84, 337-40.	3.8	11
140	Widespread multitissue deletions of the mitochondrial genome in the Pearson marrow-pancreas syndrome. Journal of Pediatrics, 1990, 117, 599-602.	1.8	79
141	Thalassemia Is Paradoxically Associated with a Reduced Risk of In-Hospital Complications and Mortality in COVID-19: Data from an International Registry. SSRN Electronic Journal, 0, , .	0.4	0